Details of the Drug Reposition

General Information of This Drug (ID: DMS1PFA)

Drug Name
SB2   DMS1PFA
Synonyms
Antimony; 7440-36-0; Stibium metallicum; Antimony, metallic; UNII-9IT35J3UV3; Antymonowodor [Polish]; UNII-0VKZ97K3UB; 0VKZ97K3UB; Antimonwasserstoffes [German]; HSDB 785; 9IT35J3UV3; UN2676; Antymon; Antimonio; Antimoine; Antimony powder; MFCD00011211; Antimonyl citrate; Antimony, ion(Sb2+); Sb2+; stibanylidyne; Antimonide; Antymonowodor; Antimon; antimony atom; Antimony, citric acid complexes; antimony(0); Antimonwasserstoffes; EINECS 270-130-2; ANTIMONOUS HYDRIDE; ACMC-1BKT5; 51Sb; EC 231-146-5; AC1NS5Q0; Sb(0); ANT
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Plaque psoriasis DISQX1LF EA90.0 Phase 3 [1]
------------------------------------------------------------------------------------
4 Application submitted Indication(s)
Indication Name Indication ID ICD-11 Status REF
Crohn disease DIS2C5Q8 DD70 Application submitted [1]
Ulcerative colitis DIS8K27O DD71 Application submitted [1]
Psoriatic arthritis DISLWTG2 FA21 Application submitted [1]
Ankylosing spondylitis DISRC6IR FA92.0 Application submitted [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)